Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising.
- As precision oncology becomes increasingly dependent on biomarker-driven therapies, smarter clinical trial design, and advanced drug delivery technologies, companies capable of integrating may be better positioned to address some of oncology’s most persistent development challenges.
- Onco-Innovations pairs a PNKP inhibitor, a DDR target distinct from PARP, with a nanoparticle delivery system in its lead candidate ONC010, and adds AI through its Inka Health subsidiary and the SynoGraph causal AI platform
- Onco-Innovations is advancing ONC010 through IND-enabling, manufacturing, and regulatory work, while using AI-enabled tools intended to support patient stratification, trial design, and evidence generation
Cancer drug development has three persistent problems. Tumors evolve resistance to therapies that once worked. Clinical trials fail often and cost enormously, frequently because the right patients are hard to identify. And many promising drugs never reach patients because they are too toxic or too difficult to deliver. For years, researchers attacked these problems separately. A newer approach treats them as connected, combining novel biology, advanced drug delivery, and artificial intelligence into a single development strategy. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is a company building at that intersection.
New Biology: Targeting DNA Repair Beyond PARP
Cancer treatments such as radiation and chemotherapy work by damaging tumor DNA. Cancer cells survive by repairing that damage, which is why DNA Damage Response (“DDR”) inhibitors have become one of oncology’s fastest-moving categories. PARP inhibitors opened the field, but newer targets are expanding it. Onco-Innovations focuses on…
NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at ibn.fm/ONNVF
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN